Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Nuvation Bio Inc.NUVB · Entity 4384 | Chief Financial Officer | July 15, 2026 | July 17, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Nuvation Bio Inc.
Report date July 15, 2026 · Filed July 17, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 54,131 |
Last balance in matching sequence
After 2026-07-15 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2026-07-15 · Exercise / conversion · Acquired 39,999 · Balance 54,130 F1: Includes 1,458 shares purchased through the issuer's employee stock purchase plan on May 19, 2026. Row 2 · 2026-07-15 · Exercise / conversion · Acquired 1 · Balance 54,131 F1: Includes 1,458 shares purchased through the issuer's employee stock purchase plan on May 19, 2026. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.17 · Expires 2034-10-06 | Direct | 662,333 |
Reported balance
After 2026-07-15 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-07-15 · Exercise / conversion · Disposed 39,999 · Balance 662,333 F2: Option vests as to 25% on the one year anniversary of October 7, 2024, and monthly thereafter over the following 36 months, subject to Reporting Person's continuous service on each such vesting date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.97 · Expires 2035-02-27 | Direct | 499,999 |
Reported balance
After 2026-07-15 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-07-15 · Exercise / conversion · Disposed 1 · Balance 499,999 F3: Option vests as to 25% on the one year anniversary of February 28, 2025, and monthly thereafter over the following 36 months, subject to Reporting Person's continuous service on each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Includes 1,458 shares purchased through the issuer's employee stock purchase plan on May 19, 2026.
F2: Option vests as to 25% on the one year anniversary of October 7, 2024, and monthly thereafter over the following 36 months, subject to Reporting Person's continuous service on each such vesting date.
F3: Option vests as to 25% on the one year anniversary of February 28, 2025, and monthly thereafter over the following 36 months, subject to Reporting Person's continuous service on each such vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 15, 2026 Filed Jul 17, 2026 22:27 UTC | Nuvation Bio Inc. NUVB · Entity 4384 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1 | $0.00 Strike: $1.97 | $0.00 |
DisclosureSEC source: 0002039891-26-000008 · form4-07172026_100715.xml · derivative · entry 4 Sauvage Philippe · CIK 0002039891 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 499,999 Underlying: Class A Common Stock · 1 shares Expires 2035-02-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Option vests as to 25% on the one year anniversary of February 28, 2025, and monthly thereafter over the following 36 months, subject to Reporting Person's continuous service on each such vesting date. Read SEC document |
| July 15, 2026 Filed Jul 17, 2026 22:27 UTC | Nuvation Bio Inc. NUVB · Entity 4384 | Exercise / conversionStock Option (Right to Buy) · Derivative | 39,999 | $0.00 Strike: $2.17 | $0.00 |
DisclosureSEC source: 0002039891-26-000008 · form4-07172026_100715.xml · derivative · entry 3 Sauvage Philippe · CIK 0002039891 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 662,333 Underlying: Class A Common Stock · 39,999 shares Expires 2034-10-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Option vests as to 25% on the one year anniversary of October 7, 2024, and monthly thereafter over the following 36 months, subject to Reporting Person's continuous service on each such vesting date. Read SEC document |
| July 15, 2026 Filed Jul 17, 2026 22:27 UTC | Nuvation Bio Inc. NUVB · Entity 4384 | Exercise / conversionClass A Common Stock | 1 | $1.97 | $1.97 |
DisclosureSEC source: 0002039891-26-000008 · form4-07172026_100715.xml · nonDerivative · entry 2 Sauvage Philippe · CIK 0002039891 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 54,131 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 1,458 shares purchased through the issuer's employee stock purchase plan on May 19, 2026. Read SEC document |
| July 15, 2026 Filed Jul 17, 2026 22:27 UTC | Nuvation Bio Inc. NUVB · Entity 4384 | Exercise / conversionClass A Common Stock | 39,999 | $2.17 | $86,797.83 |
DisclosureSEC source: 0002039891-26-000008 · form4-07172026_100715.xml · nonDerivative · entry 1 Sauvage Philippe · CIK 0002039891 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 54,130 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 1,458 shares purchased through the issuer's employee stock purchase plan on May 19, 2026. Read SEC document |
| June 23, 2026 Filed Jun 24, 2026 23:07 UTC | Nuvation Bio Inc. NUVB · Entity 4384 | Exercise / conversionStock Option (Right to Buy) · Derivative | 47,668 | $0.00 Strike: $2.17 | $0.00 |
DisclosureSEC source: 0002039891-26-000006 · form4-06242026_110612.xml · derivative · entry 3 Sauvage Philippe · CIK 0002039891 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 702,332 Underlying: Class A Common Stock · 47,668 shares Expires 2034-10-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Option vests as to 25% on the one year anniversary of October 7, 2024, and monthly thereafter over the following 36 months, subject to Reporting Person's continuous service on each such vesting date. Read SEC document |
| June 23, 2026 Filed Jun 24, 2026 23:07 UTC | Nuvation Bio Inc. NUVB · Entity 4384 | SaleClass A Common Stock | 47,668 | $6.01 | $286,370.28 |
DisclosureSEC source: 0002039891-26-000006 · form4-06242026_110612.xml · nonDerivative · entry 2 Sauvage Philippe · CIK 0002039891 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 12,673 F1 · kind: Shares sold pursuant to a 10b5-1 plan dated December 4, 2025. F2 · price: Price reported is a weighted-average sales price. The shares were sold at prices ranging from $6.00 to $6.04. The Reporting Person will provide, upon request, to the Securities and Exchange Commission, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| June 23, 2026 Filed Jun 24, 2026 23:07 UTC | Nuvation Bio Inc. NUVB · Entity 4384 | Exercise / conversionClass A Common Stock | 47,668 | $2.17 | $103,439.56 |
DisclosureSEC source: 0002039891-26-000006 · form4-06242026_110612.xml · nonDerivative · entry 1 Sauvage Philippe · CIK 0002039891 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 60,341 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 27, 2026 Filed Mar 4, 2026 01:00 UTC | Nuvation Bio Inc. NUVB · Entity 4384 | GrantStock Option (Right to Buy) · Derivative | 748,130 | $0.00 Strike: $5.91 | $0.00 |
DisclosureSEC source: 0002039891-26-000003 · form4-03042026_010301.xml · derivative · entry 2 Sauvage Philippe · CIK 0002039891 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 748,130 Underlying: Class A Common Stock · 748,130 shares Expires 2036-02-26 F2 · derivative.exercise_date: Option vests as to 25% on the one year anniversary of 2/27/2026, and monthly thereafter over the following 36 months, subject to Reporting Person's continuous service on each such vesting date. Read SEC document |
| June 17, 2025 Filed Jun 18, 2025 20:05 UTC | Nuvation Bio Inc. NUVB · Entity 4384 | PurchaseClass A Common Stock | 4,000 | $1.79 | $7,160.00 |
DisclosureSEC source: 0001415889-25-017659 · form4-06182025_040610.xml · nonDerivative · entry 2 Sauvage Philippe · CIK 0002039891 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,902 Read SEC document |
| June 16, 2025 Filed Jun 18, 2025 20:05 UTC | Nuvation Bio Inc. NUVB · Entity 4384 | PurchaseClass A Common Stock | 3,300 | $1.84 | $6,055.50 |
DisclosureSEC source: 0001415889-25-017659 · form4-06182025_040610.xml · nonDerivative · entry 1 Sauvage Philippe · CIK 0002039891 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,902 F1 · balance_after: Includes 2,602 shares acquired on May 19, 2025 under the Issuer's 2021 Employee Stock Purchase Plan. Read SEC document |
| February 28, 2025 Filed Mar 4, 2025 23:35 UTC | Nuvation Bio Inc. NUVB · Entity 4384 | GrantStock Option (Right to Buy) · Derivative | 500,000 | $0.00 Strike: $1.97 | $0.00 |
DisclosureSEC source: 0001415889-25-006701 · form4-03042025_110353.xml · derivative · entry 1 Sauvage Philippe · CIK 0002039891 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 500,000 Underlying: Class A Common Stock · 500,000 shares Expires 2035-02-27 F1 · derivative.exercise_date: Option vests as to 25% on the one year anniversary of 2/28/2025, and monthly thereafter over the following 36 months, subject to Reporting Person's continuous service on each such vesting date. Read SEC document |
| October 07, 2024 Filed Oct 9, 2024 20:09 UTC | Nuvation Bio Inc. NUVB · Entity 4384 | GrantStock Option (Right to Buy) · Derivative | 750,000 | $0.00 Strike: $2.17 | $0.00 |
DisclosureSEC source: 0001415889-24-024927 · form4-10092024_081048.xml · derivative · entry 1 Sauvage Philippe · CIK 0002039891 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 750,000 Underlying: Class A Common Stock · 750,000 shares Expires 2034-10-06 F1 · derivative.exercise_date: Option vests as to 25% on the one year anniversary of 10/7/2024, and monthly thereafter over the following 36 months, subject to Reporting Person's continuous service on each such vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.